Overexpression of Testes-Specific Protease 50 (TSP50) Predicts Poor Prognosis in Patients with Gastric Cancer

Fang Liu(Nanfang Hospital), Rongcheng Luo(Hebei Medical University), Changxuan You(Southern Medical University), Geoffrey Liu(Princess Margaret Cancer Centre), Changzhao Li(University of Alabama at Birmingham), Chuanxin Liu(Affiliated Hospital of Jining Medical University), Ling Xue(Jilin University), Qinghua Cao(Ningbo University)
Gastroenterology Research and Practice
January 1, 2014
10.1155/2014/498246
Cited by 17

Related Papers

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25
|Nature|2008|1.3k
First-Line Lorlatinib or Crizotinib in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2020|1.1k
Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)
|Annals of Oncology|2015|467
Genome-wide association analyses identify new susceptibility loci for oral cavity and pharyngeal cancer
|Nature Genetics|2016|252